Squarepoint
KRYS icon

Squarepoint’s Krystal Biotech KRYS Stock Holding History

Squarepoint’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,138
Closed -$340K – 4716
2026
Q1 		$294K Buy
+1,138
New +$303K ﹤0.01% 3731
2025
Q2 		– Sell
-81,999
Closed -$14.8M – 4785
2025
Q1 		$14.8M Buy
81,999
+72,440
+758% +$12.2M 0.02% 833
2024
Q4 		$1.5M Sell
9,559
-6,147
-39% -$1.09M ﹤0.01% 2681
2024
Q3 		$2.86M Buy
15,706
+13,298
+552% +$2.56M ﹤0.01% 1808
2024
Q2 		$442K Buy
+2,408
New +$404K ﹤0.01% 3169
2024
Q1 		– Sell
-3,709
Closed -$460K – 4315
2023
Q4 		$460K Buy
+3,709
New +$411K ﹤0.01% 3069
2022
Q4 		– Sell
-8,320
Closed -$580K – 3424
2022
Q3 		$580K Buy
+8,320
New +$601K ﹤0.01% 2132
2022
Q1 		– Sell
-21,794
Closed -$1.52M – 3210
2021
Q4 		$1.52M Buy
21,794
+8,909
+69% +$519K ﹤0.01% 1421
2021
Q3 		$673K Buy
12,885
+8,384
+186% +$496K ﹤0.01% 1800
2021
Q2 		$306K Buy
+4,501
New +$314K ﹤0.01% 2511
2020
Q3 		– Sell
-5,758
Closed -$238K – 2679
2020
Q2 		$238K Buy
+5,758
New +$277K ﹤0.01% 1731
2020
Q1 		– Sell
-11,762
Closed -$651K – 2210
2019
Q4 		$651K Sell
11,762
-20,147
-63% -$988K ﹤0.01% 1605
2019
Q3 		$1.11M Sell
31,909
-7,519
-19% -$336K 0.01% 1162
2019
Q2 		$1.59M Buy
39,428
+32,777
+493% +$1.07M 0.02% 979
2019
Q1 		$219K Buy
+6,651
New +$157K ﹤0.01% 1912
2018
Q1 		– Sell
-10,800
Closed -$114K – 1931
2017
Q4 		$114K Buy
+10,800
New +$108K ﹤0.01% 1931

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Squarepoint's KRYS Position: Q2 2026 in Review

Squarepoint sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 1,138 shares — an estimated $340K sold.

Squarepoint first reported a position in KRYS in Q4 2017 and held it in 16 quarters. The position peaked at $14.8M in Q1 2025. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Squarepoint reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 1,138 Krystal Biotech shares in Q2 2026, an estimated $340K.
  • Squarepoint first reported a position in Krystal Biotech in Q4 2017 and held it in 16 quarters.
  • Squarepoint's Krystal Biotech position peaked at $14.8M in Q1 2025.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.